Literature DB >> 24573388

Increasing cGMP-dependent protein kinase activity attenuates unilateral ureteral obstruction-induced renal fibrosis.

Wenpeng Cui1, Hasiyeti Maimaitiyiming, Xinyu Qi, Heather Norman, Qi Zhou, Xiaojun Wang, Jian Fu, Shuxia Wang.   

Abstract

Our previous studies support the protective effect of cGMP and cGMP-dependent protein kinase I (PKG-I) pathway on the development of renal fibrosis. Therefore, in the present studies, we determined whether pharmacologically or genetically increased PKG activity attenuates renal fibrosis in a unilateral ureteral obstruction (UUO) model and also examined the mechanisms involved. To increase PKG activity, we used the phosphodiesterase 5 inhibitor sildenafil and PKG transgenic mice. UUO model was induced in wild-type or PKG-I transgenic mice by ligating the left lateral ureteral and the renal fibrosis was observed after 14 days of ligation. Sildenafil was administered into wild-type UUO mice for 14 days. In vitro, macrophage and proximal tubular cell function was also analyzed. We found that sildenafil treatment or PKG transgenic mice had significantly reduced UUO-induced renal fibrosis, which was associated with reduced TGF-β signaling and reduced macrophage infiltration into kidney interstitial. In vitro data further demonstrated that both macrophages and proximal tubular cells were important sources of UUO-induced renal TGF-β levels. The interaction between macrophages and tubular cells contributes to TGF-β-induced renal fibrosis. Taken together, these data suggest that increasing PKG activity ameliorates renal fibrosis in part through regulation of macrophage and tubular cell function, leading to reduced TGF-β-induced fibrosis.

Entities:  

Keywords:  PKG; TGF-β1; UUO; renal fibrosis

Mesh:

Substances:

Year:  2014        PMID: 24573388      PMCID: PMC4010679          DOI: 10.1152/ajprenal.00657.2013

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  31 in total

Review 1.  It's a Smad world: regulation of TGF-beta signaling in the kidney.

Authors:  H William Schnaper; Tomoko Hayashida; Anne-Christine Poncelet
Journal:  J Am Soc Nephrol       Date:  2002-04       Impact factor: 10.121

2.  Overexpression of cGMP-dependent protein kinase I (PKG-I) attenuates ischemia-reperfusion-induced kidney injury.

Authors:  Yanzhang Li; Xiaopeng Tong; Hasiyeti Maimaitiyiming; Kate Clemons; Ji-Min Cao; Shuxia Wang
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

Review 3.  Mechanisms of interstitial fibrosis in obstructive nephropathy.

Authors:  J R Diamond; S D Ricardo; S Klahr
Journal:  Semin Nephrol       Date:  1998-11       Impact factor: 5.299

Review 4.  Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects.

Authors:  A Smolenski; A M Burkhardt; M Eigenthaler; E Butt; S Gambaryan; S M Lohmann; U Walter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1998-07       Impact factor: 3.000

5.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

6.  Expression of constitutively active cGMP-dependent protein kinase prevents glucose stimulation of thrombospondin 1 expression and TGF-beta activity.

Authors:  Shuxia Wang; Xing Wu; Thomas M Lincoln; Joanne E Murphy-Ullrich
Journal:  Diabetes       Date:  2003-08       Impact factor: 9.461

Review 7.  Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy.

Authors:  Robert L Chevalier; Michael S Forbes; Barbara A Thornhill
Journal:  Kidney Int       Date:  2009-04-01       Impact factor: 10.612

Review 8.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

9.  The cyclic GMP-dependent protein kinase Iα suppresses kidney fibrosis.

Authors:  Elisabeth Schinner; Andrea Schramm; Frieder Kees; Franz Hofmann; Jens Schlossmann
Journal:  Kidney Int       Date:  2013-06-12       Impact factor: 10.612

10.  Fibrosis in the kidney: is a problem shared a problem halved?

Authors:  Tim D Hewitson
Journal:  Fibrogenesis Tissue Repair       Date:  2012-06-06
View more
  13 in total

1.  Differences in the renal antifibrotic cGMP/cGKI-dependent signaling of serelaxin, zaprinast, and their combination.

Authors:  Veronika Wetzl; Elisabeth Schinner; Frieder Kees; Lothar Faerber; Jens Schlossmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-28       Impact factor: 3.000

2.  P311 promotes renal fibrosis via TGFβ1/Smad signaling.

Authors:  Zhihui Yao; Sisi Yang; Weifeng He; Lian Li; Rui Xu; Xiaorong Zhang; Haisheng Li; Rixing Zhan; Wei Sun; Jianglin Tan; Junyi Zhou; Gaoxing Luo; Jun Wu
Journal:  Sci Rep       Date:  2015-11-30       Impact factor: 4.379

3.  Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.

Authors:  Wim Scheele; Susan Diamond; Jeremy Gale; Valerie Clerin; Nihad Tamimi; Vu Le; Rosalind Walley; Fernando Grover-Páez; Christelle Perros-Huguet; Timothy Rolph; Meguid El Nahas
Journal:  J Am Soc Nephrol       Date:  2016-04-25       Impact factor: 10.121

Review 4.  Cyclic nucleotide signalling in kidney fibrosis.

Authors:  Elisabeth Schinner; Veronika Wetzl; Jens Schlossmann
Journal:  Int J Mol Sci       Date:  2015-01-22       Impact factor: 5.923

5.  Inhibition of the TGFβ signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis.

Authors:  Elisabeth Schinner; Veronika Wetzl; Andrea Schramm; Frieder Kees; Peter Sandner; Johannes-Peter Stasch; Franz Hofmann; Jens Schlossmann
Journal:  FEBS Open Bio       Date:  2017-03-01       Impact factor: 2.693

6.  The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.

Authors:  Roger Flores-Costa; José Alcaraz-Quiles; Esther Titos; Cristina López-Vicario; Mireia Casulleras; Marta Duran-Güell; Bibiana Rius; Alba Diaz; Katherine Hall; Courtney Shea; Renee Sarno; Mark Currie; Jaime L Masferrer; Joan Clària
Journal:  Br J Pharmacol       Date:  2018-01-31       Impact factor: 8.739

Review 7.  Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review.

Authors:  Georgios Georgiadis; Ioannis-Erineos Zisis; Anca Oana Docea; Konstantinos Tsarouhas; Irene Fragkiadoulaki; Charalampos Mavridis; Markos Karavitakis; Stavros Stratakis; Kostas Stylianou; Christina Tsitsimpikou; Daniela Calina; Nikolaos Sofikitis; Aristidis Tsatsakis; Charalampos Mamoulakis
Journal:  J Clin Med       Date:  2020-04-29       Impact factor: 4.241

8.  Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin.

Authors:  Veronika Wetzl; Elisabeth Schinner; Frieder Kees; Franz Hofmann; Lothar Faerber; Jens Schlossmann
Journal:  Front Pharmacol       Date:  2016-07-12       Impact factor: 5.810

Review 9.  Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension.

Authors:  Evanthia Mergia; Johannes Stegbauer
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

10.  Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats.

Authors:  Szabina Czirok; Lilla Fang; Tamás Radovits; Gábor Szabó; Gábor Szénási; László Rosivall; Béla Merkely; Gábor Kökény
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.